BRIEF published on 02/16/2026 at 07:35, 3 months 5 days ago Nicox reçoit un avis favorable de la FDA concernant sa demande d'autorisation de mise sur le marché (NDA) pour le NCX 470. FDA Nicox Traitement Du Glaucome NCX 470 Soumission D'un Accord De Confidentialité
BRIEF published on 02/16/2026 at 07:35, 3 months 5 days ago Nicox Receives Positive Feedback from FDA for NCX 470 NDA FDA Nicox Glaucoma Treatment NCX 470 NDA Submission
BRIEF published on 02/16/2026 at 07:35, 3 months 5 days ago Nicox prépare une soumission de NDA pour NCX 470 après avis positif de la FDA FDA NDA Nicox NCX 470 Glaucome
BRIEF published on 02/16/2026 at 07:35, 3 months 5 days ago Nicox is preparing an NDA submission for NCX 470 following a positive FDA opinion FDA Glaucoma NDA Nicox NCX 470
PRESS RELEASE published on 02/16/2026 at 07:30, 3 months 5 days ago Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 Nicox receives positive feedback from pre-NDA meeting with U.S. FDA for NCX 470, on track for NDA submission in summer 2026. NCX 470 lowers intraocular pressure in glaucoma patients FDA Nicox NCX 470 Intraocular Pressure Pre-NDA
PRESS RELEASE published on 02/16/2026 at 07:30, 3 months 5 days ago Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470 Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470, confirmant le dépôt de la NDA pour l'été 2026. Collaboration avec Kowa et avancée vers l'autorisation de mise sur le marché FDA Nicox NCX 470 Réunion Pré-NDA Autorisation De Marché
BRIEF published on 02/12/2026 at 07:35, 3 months 9 days ago Nicox maintient son statut PEA-PME pour 2026 PEA-PME Euronext Growth Paris Investissement Ophtalmologie Nicox
BRIEF published on 02/12/2026 at 07:35, 3 months 9 days ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
PRESS RELEASE published on 02/12/2026 at 07:30, 3 months 9 days ago Nicox confirme son éligibilité au PEA-PME Nicox confirme son éligibilité au PEA-PME pour l'année à venir, permettant aux investisseurs de continuer à intégrer ses actions dans les comptes PEA PME PEA-PME Investissement Fiscalité Ophtalmologie Nicox
BRIEF published on 02/10/2026 at 07:35, 3 months 11 days ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
Published on 05/21/2026 at 23:00, 7 hours 47 minutes ago Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 7 hours 47 minutes ago Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 7 hours 47 minutes ago Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 8 hours 32 minutes ago Linear Announces Acquisition, Share Consolidation and Private Placement
Published on 05/22/2026 at 06:35, 11 minutes ago VARON Highlights Respiratory Wellness and Active Aging Ahead of Pentecost in Germany
Published on 05/22/2026 at 05:10, 1 hour 36 minutes ago ZPMC Launches Automated Production Line for Compact Enclosures
Published on 05/22/2026 at 04:50, 1 hour 56 minutes ago ZPMC Highlights Marine Engineering and Steel Bridge Manufacturing Capabilities on Media Open Day
Published on 05/22/2026 at 04:40, 2 hours 6 minutes ago Xinhua Silk Road: Anhui launches innovation and entrepreneurship contest to attract global sci-tech talents
Published on 05/21/2026 at 17:45, 13 hours 2 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 13 hours 2 minutes ago CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 16:35, 14 hours 11 minutes ago 260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026
